RKI drops may protect endothelial cells post-cataract surgery
Research

RKI drops may protect endothelial cells post-cataract surgery

Topical rho kinase inhibitors potentially reduce endothelial cell loss following cataract surgery.
Beacon Therapeutics doses first patient in VISTA XLRP gene therapy trial
Pipeline

Beacon Therapeutics doses first patient in VISTA XLRP gene therapy trial

Randomized study is investigating AGTC-501 for the treatment of patients diagnosed with x-linked retinitis pigmentosa.
Skye shifting away from eye care after phase 2 glaucoma study fails
Pipeline

Skye shifting away from eye care after phase 2 glaucoma study fails

Clinical trial evaluating SBI-100 OE did not achieve statistical significance in improving IOP for patients with POAG and OHT.
How effective are blue-light filtering IOLs in reducing macular atrophy?
Research

How effective are blue-light filtering IOLs in reducing macular atrophy?

New study compares effectiveness of BLF IOLs and non-BLF IOLs for lowering the MA progression in nAMD.
Oculis reports positive phase 2b topline data on licaminlimab for DED
Pipeline

Oculis reports positive phase 2b topline data on licaminlimab for DED

OSC-02 eye drop demonstrates rapid treatment effect on corneal inflammation as early as 2 weeks of treatment.
Bausch + Lomb to launch INFUSE for Astigmatism SiHy lenses in the US
Products

Bausch + Lomb to launch INFUSE for Astigmatism SiHy lenses in the US

Latest one-day silicone hydrogel lens addition maintains 96% of moisture for 16 hours.
Air pollutants linked to increased AMD risk
Research

Air pollutants linked to increased AMD risk

New research examined the potential detrimental impact of ambient air pollution on AMD.
BostonSight introduces scleral lens fitting consultation program
Events

BostonSight introduces scleral lens fitting consultation program

“Beyond the Fit” features multiple programs designed to provide lens practitioners with tools to fit patients with a range of ocular conditions.
Sightpath Medical now owns LASIK provider PennVista
Business

Sightpath Medical now owns LASIK provider PennVista

Provider of mobile ophthalmic services adds all-in-one provider of ophthalmic surgery services to its growing presence across the United States.
CRISPR gene editing may prevent early-onset vision loss
Research

CRISPR gene editing may prevent early-onset vision loss

BRILLIANCE trial examines safety and efficacy of a single injection genome editing medication in 14 LCA patients.
Nidek introduces the RS-1 Glauvus OCT system
Products

Nidek introduces the RS-1 Glauvus OCT system

Newest ophthalmic diagnostic technology features up to 250 kHz scan speed with deep learning-based analytics for retinal and glaucoma assessments.
Negative dry eye symptoms linked to silicone hydrogel lenses
Research

Negative dry eye symptoms linked to silicone hydrogel lenses

Researchers investigate the impact of silicone hydrogel lenses on the eye.
Researchers update the AREDS Simplified Severity Scale
Research

Researchers update the AREDS Simplified Severity Scale

Findings from new post-hoc analysis modernize the AREDS Simplified Severity Scale with two key updates.
First patient dosed in phase 3 study on needle- and opioid-free sedation for cataract surgery
Pipeline

First patient dosed in phase 3 study on needle- and opioid-free sedation for cataract surgery

Melt Pharmaceuticals’ rapid-dissolving tablet intends to offer greater patient comfort during sedation without the need for needles or opioids.
Harrow reports 52-week data from phase 3 VEVYE extension study
Research

Harrow reports 52-week data from phase 3 VEVYE extension study

FDA-approved cyclosporine solution to treat DED sustains statistically significant improvements in safety and efficacy, with continuous tear production improvements.
How accurate are at-home vision tests for wet AMD?
Research

How accurate are at-home vision tests for wet AMD?

A new study evaluated three home-monitoring tests for diagnostic accuracy of nAMD.
Bausch + Lomb launches Blink NutriTears for dry eye
Products

Bausch + Lomb launches Blink NutriTears for dry eye

Newest addition to the Blink product line targets root cause of disease; clinically proven to provide symptom relief in as little as 2 weeks.
Ocular Therapeutix to cut 13% of workforce
Business

Ocular Therapeutix to cut 13% of workforce

Company cites new initiative to prioritize clinical development of its axitinib intravitreal implant for wet AMD, currently in a phase 3 trial.
Atropine 0.05% for myopia shows promise in 5-year LAMP study
Research

Atropine 0.05% for myopia shows promise in 5-year LAMP study

Extended data builds on prior 1-year and 3-year findings regarding atropine effectiveness for childhood myopia.
First patient enrolled in Azura's phase 3 MGD trial for AZR-MD-001
Pipeline

First patient enrolled in Azura's phase 3 MGD trial for AZR-MD-001

New study on selenium sulfide ointment follows positive phase 2 data supporting its ability to target the pathophysiology of MGD.